Enlivex Therapeutics (ENLV) said Wednesday it received a notice of allowance from the Japanese Patent Office for a patent application focused on the use of Allocetra in osteoarthritis patients.
The patent, which will secure the company's intellectual property rights in Japan until 2040, is expected to be officially issued by the end of Q2 2025, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。